Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed prostate cancer (closed to accrual as of 3/9/2005)
• •* Prior therapy on protocol NCI-00-C-0137 or NCI-00-C-0154
• •* Progressive disease (2 consecutively rising PSA levels, new bone scan lesion, or progression of soft tissue)
• •* PSA at least 5 ng/mL
• •* Progressive androgen-independent disease
• •* Disease progression at least 4 weeks after flutamide withdrawal OR
• •* Disease progression at least 6 weeks after bicalutamide or nilutamide withdrawal OR
• •Histologically confirmed follicular or mantle cell non-Hodgkin's lymphoma (mantle cell lymphoma closed to accrual as of 3/9/2005)
• •* Prior therapy on protocol NCI-00-C-0133, NCI-01-C-0169, or NCI-00-C-0050
• •* Progressive disease after standard treatment
• •* Relapsed disease OR
• •Histologically confirmed colon cancer (colon cancer closed to accrual as of 9/28/05)
• •* Prior therapy on protocol NCI-99-C-0023
• •* Progressive disease OR
• •Histologically confirmed non-Hodgkin's lymphoma or Hodgkin's lymphoma
• •* Progressive disease after standard treatment
• •* No curative therapy exists
• •* Prior allogeneic stem cell transplantation from a matched sibling or matched unrelated donor for an aggressive lymphoma allowed
• •* Last infusion of allogeneic cells (either hematopoietic stem cells or donor lymphocytes) must have occurred \> 90 days prior to study enrollment
• •No other standard therapy available or refused such therapy
• •No symptomatic or rapidly progressive malignancy requiring therapy
• •No symptomatic CNS metastases
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 80-100%
• •Life expectancy
• •More than 2 months
• •Hematopoietic
• •WBC at least 2,500/mm\^3
• •Granulocyte count at least 1,500/mm\^3
• •Platelet count at least 50,000/mm\^3
• •Hemoglobin at least 10 g/dL
• •Hematocrit at least 30%
• •Hepatic
• •Bilirubin no greater than 3.0 mg/dL (unless due to Gilbert's disease)
• •SGOT and SGPT no greater than 3 times upper limit of normal
• •Hepatitis B surface antigen negative
• •Hepatitis C antibody negative
• •Renal
• •Creatinine no greater than 2.0 mg/dL
• •Immunologic
• •HIV negative
• •Rheumatoid factor negative if history or evidence of arthritis
• •Anti-nuclear antibody (ANA) titer no greater than 1:80 if history or clinical signs or symptoms of connective tissue disease
• •No prior or active autoimmune disease (e.g., uveitis, rheumatoid arthritis, lupus erythematosus, autoimmune hemolytic anemia, ulcerative and hemorrhagic colitis, endocrine disorders \[e.g., thyroiditis, hyperthyroidism, hypothyroidism, autoimmune hypophysitis/hypopituitarism, or adrenal insufficiency\], sarcoid granuloma, myasthenia gravis, polymyositis,or Guillain-Barre syndrome)
• •No positive antibody titers to autoimmune diseases
• •* Rheumatoid factor positive allowed unless ANA titer is greater than 1:80 and there is a history of or clinical signs or symptoms of connective tissue disease
• •No active infection
• •Other
• •No other active malignancy within the past 5 years except adequately treated squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 4 months after study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •See Disease Characteristics
• •Recovered from prior vaccine therapy
• •No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4) for patients in part I of study
• •* Patients in part II of study may have had up to 4 prior treatments with MDX-CTLA4
• •No concurrent vaccine therapy
• •No concurrent infliximab
• •Chemotherapy
• •At least 4 weeks since prior cytotoxic chemotherapy
• •No concurrent mercaptopurine, methotrexate, or cyclophosphamide
• •Endocrine therapy
• •See Disease Characteristics
• •At least 4 weeks since prior steroids
• •No concurrent systemic, inhaled, or topical steroids
• •Radiotherapy
• •At least 4 weeks since prior radiotherapy
• •Surgery
• •At least 4 weeks since prior major surgery
• •Other
• •Prior intervening therapy for prostate cancer, non-Hodgkin's lymphoma or colon cancer allowed
• •No other concurrent investigational therapy
• •No other concurrent immunosuppressants (e.g., cyclosporine or its analog)